Roberta Zappasodi - Concepedia

Author

Roberta Zappasodi

Cornell University ORCID

Also Known As

Mohsen Abu-Akeel, R Zappasodi, R. Zappasodi, Roberta Zappasodi, Sara Valpione, Yan Lan, Zappasodi, Roberta

227

Publications

15K

Citations

H-Index

Concepts

All Affiliations

Cornell University Memorial Sloan Kettering Cancer Center Parker Institute for Cancer Immunotherapy Swim Across America Weill Cornell Medicine

About

Roberta Zappasodi is an author at Cornell University specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	2.7K
2	Immunology	14	15	2.2K
3	Cell Biology	13	13	2.1K
4	Allergy	1	1	14
5	Molecular Medicine	1	1	18

Roberta Zappasodi

Publications

11.9K

Citations

H-Index

Page 1

	Year	Citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Science	2015	7.8K
Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors Shihao Xu, Omkar Chaudhary, Patricia Rodríguez-Morales, Immunity Cancer ImmunosurveillanceLipid PeroxidationImmunologyImmunoeditingScavenger Receptor Cd36	2021	673
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors Haiping Wang, Fabien Franco, Yao-Chen Tsui, Nature Immunology Cancer ImmunosurveillanceMedicineT-regulatory CellImmunologyImmunoediting	2020	609
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine Luís Felipe Campesato, Sadna Budhu, Jeremy H. Tchaicha, Nature Communications	2020	418
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours Roberta Zappasodi, Inna Serganova, Ivan Cohen, Nature Cancer ImmunosurveillanceOncologyMedicineTumor ImmunityImmune Checkpoint Inhibitor	2021	373
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce Harriet M. Kluger, Hussein A. Tawbi, Maria Libera Ascierto, Journal for ImmunoTherapy of Cancer New AgentsImmunologyImmunoeditingImmunotherapyTumor Resistance	2020	260
Rational design of anti-GITR-based combination immunotherapy Roberta Zappasodi, Cynthia A. Sirard, Yanyun Li, Nature Medicine Rational DesignImmunologyBiological TherapyImmunomodulationImmunotherapy	2019	224
Non-conventional Inhibitory CD4+Foxp3−PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity Roberta Zappasodi, Sadna Budhu, Matthew D. Hellmann, Cancer Cell Cancer ImmunosurveillanceAutoimmune DiseaseT-regulatory CellImmunologyTumor Immunity	2018	138
Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death Roberta Zappasodi, Serenella M. Pupa, Gaia C. Ghedini, Cancer Research	2010	134
Hallmarks of Resistance to Immune-Checkpoint Inhibitors Maria Karasarides, Alexandria P. Cogdill, Paul B. Robbins, Cancer Immunology Research	2022	120

Page 1